Relapsing forms of multiple sclero- sis (MS) where it reduces the frequency of clini- cal exacerbations and delays the accumulation of physical disability.
0.5mg OD (with or without food)
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, thus preventing them from contributing to an autoimmune reaction.
It may increase risks of infections; delay treatment in case of suspicion or diagnosis of progressive multifocal leukoencephalopathy or basal cell carcinoma; monitor liver functions before and during treatment; monitor fundus before and 3 - 4 months after initiation of treat- ment.
Allergy to the drug or its excipients; myocardial infarction; unstable angi- na; stroke; transient ischemic attack; decompen- sated heart failure with hospitalization; Class III/IV heart failure; treatment with Class Ia or Class III anti-arrhythmic drugs; Baseline QTc interval ≥500 msec; history of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (unless patient has a pacemaker).
Headache; diarrhea; cough; influen- za; sinusitis; back pain; abdominal pain; pain in extremity and liver transaminase elevation.
No administration of live attenuated vaccines during, and for 2 months after stopping treatment with the drug; ketoconazole
It was derived from myriocin (an immunosuppressive natural prod- uct).